Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study - PubMed (original) (raw)
. 2000 Oct;32(4 Pt 1):689-92.
doi: 10.1053/jhep.2000.17894.
Affiliations
- PMID: 11003611
- DOI: 10.1053/jhep.2000.17894
Free article
Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study
A Poonawala et al. Hepatology. 2000 Oct.
Free article
Abstract
It has recently been suggested that nonalcoholic steatohepatitis (NASH) is an under-recognized cause of cryptogenic cirrhosis (CC) on the basis of higher prevalence of obesity and type II diabetes among these patients. To test this hypothesis, we studied 65 consecutive patients with advanced cirrhosis (Child-Pugh Score >/= 7) of undetermined etiology (CC) from our active waiting list for liver transplantation in January 1993, 1996, and 1999. For each patient, we selected 2 age- and sex-matched controls from the corresponding lists. The prevalence of obesity (defined as body mass index [BMI] >/= 30) and diabetes were compared between the groups. Sixteen patients (and their 32 controls) with CC were excluded as further review of records suggested other possible etiologies. Thus, the final analysis included 49 patients and 98 controls. The etiology of cirrhosis in the control group was alcohol in 16.3%, chronic viral hepatitis in 30.6%, autoimmune hepatitis in 8.2%, and primary biliary cirrhosis (PBC) or primary sclerosing cholangitis in 35.7%. The prevalence of obesity (55% vs. 24%) and type II diabetes (47% vs. 22%) was significantly higher in patients with CC compared with controls. Twenty-three percent of patients with CC had both obesity and diabetes compared with 5% among controls (P =.002). There was no difference in the prevalence of hypercholesterolemia (serum cholesterol > 200 mg/dL) between the groups. In conclusion, patients with advanced CC are more likely to be obese and diabetic compared with age- and sex-matched patients with advanced cirrhosis. This supports the hypothesis that NASH may be an etiological factor in some of the patients with CC.
Similar articles
- Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.
Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Caldwell SH, et al. Hepatology. 1999 Mar;29(3):664-9. doi: 10.1002/hep.510290347. Hepatology. 1999. PMID: 10051466 - Clinical characteristics of patients with cryptogenic liver cirrhosis in Okinawa, Japan.
Sakugawa H, Nakasone H, Nakayoshi T, Kawakami Y, Yamashiro T, Maeshiro T, Kobashigawa K, Kinjo F, Saito A. Sakugawa H, et al. Hepatogastroenterology. 2003 Nov-Dec;50(54):2005-8. Hepatogastroenterology. 2003. PMID: 14696453 - Prevalence of obesity, diabetes mellitus and hyperlipidaemia in patients with cryptogenic liver cirrhosis.
Duseja A, Nanda M, Das A, Das R, Bhansali A, Chawla Y. Duseja A, et al. Trop Gastroenterol. 2004 Jan-Mar;25(1):15-7. Trop Gastroenterol. 2004. PMID: 15303464 - Non-alcoholic steatohepatitis in children.
Nanda K. Nanda K. Pediatr Transplant. 2004 Dec;8(6):613-8. doi: 10.1111/j.1399-3046.2004.00241.x. Pediatr Transplant. 2004. PMID: 15598336 Review. - [Non-alcoholic fatty liver: 10 years' experience at the Insituto Nacional de la Nutrición Salvador Zubirán].
de la Mora G, Olivera M, de la Cerda R, Arista J, Kershenobich D, Uribe M. de la Mora G, et al. Rev Invest Clin. 1994 Mar-Apr;46(2):85-92. Rev Invest Clin. 1994. PMID: 8052745 Review. Spanish.
Cited by
- TIMP3 overexpression in macrophages protects from insulin resistance, adipose inflammation, and nonalcoholic fatty liver disease in mice.
Menghini R, Casagrande V, Menini S, Marino A, Marzano V, Hribal ML, Gentileschi P, Lauro D, Schillaci O, Pugliese G, Sbraccia P, Urbani A, Lauro R, Federici M. Menghini R, et al. Diabetes. 2012 Feb;61(2):454-62. doi: 10.2337/db11-0613. Epub 2012 Jan 6. Diabetes. 2012. PMID: 22228717 Free PMC article. - Non-alcoholic Fatty Liver Disease: East Versus West.
Agrawal S, Duseja AK. Agrawal S, et al. J Clin Exp Hepatol. 2012 Jun;2(2):122-34. doi: 10.1016/S0973-6883(12)60101-7. Epub 2012 Jul 21. J Clin Exp Hepatol. 2012. PMID: 25755421 Free PMC article. - Hepatoprotective Effects of MHY3200 on High-Fat, Diet-Induced, Non-Alcoholic Fatty Liver Disease in Rats.
Kim MJ, Park CH, Kim DH, Park MH, Park KC, Hyun MK, Lee AK, Moon HR, Chung HY. Kim MJ, et al. Molecules. 2018 Aug 16;23(8):2057. doi: 10.3390/molecules23082057. Molecules. 2018. PMID: 30115876 Free PMC article. - Dietary composition and nonalcoholic fatty liver disease.
Solga S, Alkhuraishe AR, Clark JM, Torbenson M, Greenwald A, Diehl AM, Magnuson T. Solga S, et al. Dig Dis Sci. 2004 Oct;49(10):1578-83. doi: 10.1023/b:ddas.0000043367.69470.b7. Dig Dis Sci. 2004. PMID: 15573908 - Non-Alcoholic Fatty Liver Disease (NAFLD) in Obesity.
Patell R, Dosi R, Joshi H, Sheth S, Shah P, Jasdanwala S. Patell R, et al. J Clin Diagn Res. 2014 Jan;8(1):62-6. doi: 10.7860/JCDR/2014/6691.3953. Epub 2013 Jan 12. J Clin Diagn Res. 2014. PMID: 24596725 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical